SCHEMBL2802360

SCHEMBL2802360

CCOC(=O)c1cnn2c(Nc3cc(C)ccc3F)c(C(=O)N3CCC4(CC3)COc3cc(F)ccc34)cnc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
ALDH1A1 P00352 6/20 0.36
HPGD P15428 3/20 0.36
HSD17B10 Q99714 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
GAA P10253 2/20 0.34
BRAF P15056 1/20 0.34
IDO1 P14902 1/20 0.34
TDO2 P48775 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
USP2 O75604 1/20 0.34
TSHR P16473 1/20 0.34
KDR P35968 1/20 0.34
AVPR1A P37288 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2801683 0.95 KDM4E (0.36) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL2801354 0.94 NPC1 (0.38) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL2800216 0.93 AVPR1A (0.41) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL2801436 0.92 SMN1; SMN2 (0.39) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL2802330 0.92 IDO1 (0.36) KDM4EALDH1A1LMNAMAPTIDO1
SCHEMBL2799661 0.91 KDM4E (0.38) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL2801643 0.90 KDR (0.42) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL2799602 0.89 IDO1 (0.33) KDM4EALDH1A1HPGDLMNAIDO1
SCHEMBL2800927 0.89 SMN1; SMN2 (0.39) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL2803128 0.88 BRAF (0.37) KDM4ENPC1RAB9AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 KDM4E 3180/4885NPC1 1787/4885RAB9A 3259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.